SCHEMBL4508447

SCHEMBL4508447

COc1ccc(-c2sc(CNS(=O)(=O)c3ccc(Cl)s3)cc2-c2ccc(Cl)cc2Cl)cc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.45
MEN1 O00255 3/20 0.45
CNR1 P21554 2/20 0.43
MAPT P10636 1/20 0.41
PTPN2 P17706 3/20 0.40
PTPN1 P18031 3/20 0.40
PTPN5 P54829 3/20 0.40
AKR1C3 P42330 1/20 0.39
AKR1C2 P52895 1/20 0.39
SMN1; SMN2 Q16637 3/20 0.39
TSHR P16473 2/20 0.39
PSEN1 P49768 1/20 0.39
PSEN2 P49810 1/20 0.39
APH1B Q8WW43 1/20 0.39
NCSTN Q92542 1/20 0.39
APH1A Q96BI3 1/20 0.39
PSENEN Q9NZ42 1/20 0.39
TP53 P04637 1/20 0.38
THRB P10828 1/20 0.38
HPGD P15428 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4488378 0.88 MAPT (0.52) KMT2AMEN1CNR1MAPTSMN1; SMN2
SCHEMBL4494987 0.87 ALDH1A1 (0.47) KMT2AMEN1CNR1MAPTSMN1; SMN2
SCHEMBL4487171 0.87 KMT2A (0.46) KMT2AMEN1CNR1SMN1; SMN2TSHR
SCHEMBL4508001 0.85 CNR1 (0.43) KMT2AMEN1CNR1MAPTSMN1; SMN2
SCHEMBL4505757 0.85 PGR (0.48) KMT2AMEN1CNR1MAPTSMN1; SMN2
SCHEMBL4480858 0.84 KMT2A (0.41) KMT2AMEN1CNR1MAPTSMN1; SMN2
SCHEMBL4486476 0.84 HPGD (0.42) KMT2AMEN1MAPTSMN1; SMN2TSHR
SCHEMBL4491425 0.84 FLT1 (0.47) KMT2AMEN1MAPTSMN1; SMN2HPGD
SCHEMBL4488977 0.84 MAPT (0.42) KMT2AMEN1CNR1MAPTSMN1; SMN2
SCHEMBL4496378 0.84 MAPT (0.51) KMT2AMEN1CNR1MAPTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7589120-B2 N-[(4,5-diphenyl-2-thienyl)methyl]sulfonamide derivatives, preparation thereof and their therapeutic application SANOFI-AVENTIS (FR) 2009-09-15 US claimed
US-20070287744-A1 N-[(4,5-DIPHENYL-2-THIENYL)METHYL]SULFONAMIDE DERIVATIVES, PREPARATION THEREOF AND THEIR THERAPEUTIC APPLICATION SANOFI-AVENTIS (FR) 2007-12-13 US claimed
US-7589120-B2 N-[(4,5-diphenyl-2-thienyl)methyl]sulfonamide derivatives, preparation thereof and their therapeutic application SANOFI-AVENTIS (FR) 2009-09-15 US disclosed
US-20070287744-A1 N-[(4,5-DIPHENYL-2-THIENYL)METHYL]SULFONAMIDE DERIVATIVES, PREPARATION THEREOF AND THEIR THERAPEUTIC APPLICATION SANOFI-AVENTIS (FR) 2007-12-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070287744-A1 N-[(4,5-DIPHENYL-2-THIENYL)METHYL]SULFONAMIDE DERIVATIVES, PREPARATION THEREOF AND THEIR THERAPEUTIC APPLICATION TPMT, TXNRD2, ARG2 KMT2A 1401/4885MEN1 3505/4885CNR1 60/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.